Informationen:
Fehler:
ID
22792
Beschreibung
Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B; ODM derived from: https://clinicaltrials.gov/show/NCT00606099
Link
https://clinicaltrials.gov/show/NCT00606099
Stichworte
Versionen (1)
- 12.06.17 12.06.17 -
Hochgeladen am
12. Juni 2017
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Chronic Hepatitis B NCT00606099
Eligibility Chronic Hepatitis B NCT00606099
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Chronic Hepatitis B NCT00606099
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
ID.1
Item
male or female, at least 18 years of age.
boolean
C0001779 (UMLS CUI [1])
ID.2
Item
patients with compensated chronic hepatitis b who are currently receiving adefovir 10mg once daily.
boolean
C0524909 (UMLS CUI [1,1])
C0050175 (UMLS CUI [1,2])
C0050175 (UMLS CUI [1,2])
ID.3
Item
patients must have received adefovir 10mg once daily for at least 48 weeks continuously and have a sub-optimal response to adefovir therapy (≥4log10 copies of hbv dna/ml).
boolean
C0050175 (UMLS CUI [1,1])
C0521982 (UMLS CUI [1,2])
C0521982 (UMLS CUI [1,2])
ID.4
Item
patient is willing to comply with all study requirements.
boolean
C0679823 (UMLS CUI [1])
ID.5
Item
patient is willing and able to provide written informed consent.
boolean
C0021430 (UMLS CUI [1])
ID.6
Item
pregnant or nursing (lactating) women. all women must have a negative pregnancy test at the screening visit.
boolean
C0549206 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0427780 (UMLS CUI [1,3])
C0006147 (UMLS CUI [1,2])
C0427780 (UMLS CUI [1,3])
ID.7
Item
female patients of reproductive potential is unwilling to use double barrier method of contraception (condom plus spermicide or diaphragm plus spermicide).
boolean
C0004764 (UMLS CUI [1])
ID.8
Item
patient is co-infected with hepatitis c virus or hiv.
boolean
C0275524 (UMLS CUI [1,1])
C0019196 (UMLS CUI [1,2])
C0019682 (UMLS CUI [1,3])
C0019196 (UMLS CUI [1,2])
C0019682 (UMLS CUI [1,3])
ID.9
Item
patient has previously taken lamivudine.
boolean
C0209738 (UMLS CUI [1])
ID.10
Item
patient is currently abusing illicit drugs or alcohol.
boolean
C0013146 (UMLS CUI [1,1])
C0085762 (UMLS CUI [1,2])
C0085762 (UMLS CUI [1,2])
ID.11
Item
patient is using any investigational drugs or with in the last 30 days.
boolean
C0013230 (UMLS CUI [1])
ID.12
Item
patient is enrolled or plans to enroll in a clinical study involving investigational drug.
boolean
C0013230 (UMLS CUI [1])
ID.13
Item
patient has a history of pancreatitis, hepatic decompsensation, hepatocellular carcinoma, or a history of hypersensitivity to telbivudine or adfovir.
boolean
C0679831 (UMLS CUI [1])
ID.14
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean
C0242801 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])